FAM3C and cancer: To investigate the clinical relevance of this finding, we successfully purified and validated EVs from plasma samples of NSCLC patients and healthy individuals (Figure S2A), and measured EV FAM3C expression by immunoblotting in 84 plasma samples (Figure 1E) and ELISA in 213 plasma samples (Figure 1F), demonstrating significantly higher FAM3C in cancer patients.